×
About 94,788 results

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04941274

May 20th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is most common in people with HIV but may also occur in patients without a diagnosis of HIV. Patients with HIV-associated KS have worse survival than HIV-i...

Pregnant Women Vaccinated Against Covid-19.
https://clinicaltrials.gov/ct2/show/NCT04957953

May 20th, 2022 - Establish a cohort of pregnant women exposed to a COVID19 vaccine, whether or not they have experienced an adverse event, to assess the potential effects of vaccines on the course of pregnancy, on the fetus or newborn and on the mother.

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
https://clinicaltrials.gov/ct2/show/NCT04902443

May 20th, 2022 - Background: There is an unmet need for less toxic and more effective treatments for virus-associated malignancies. Pomalidomide induces polyfunctional T cell, NK cell, and dendritic cell activation. Pomalidomide has shown promising activity in Kaposi sarcoma, likely due in part to immune modulation. Downregulation and/or deregulation of immune surface markers by viruses can thwart immunologic t...

The Impact of the COVID-19 Pandemic on Eating Behavior and Weight Change
https://clinicaltrials.gov/ct2/show/NCT04896060

May 20th, 2022 - Study Description: We will recruit previous NIDDK study participants as well as newly recruited individuals from the general population to examine how the COVID-19 pandemic has exacerbated the impact of psychosocial stressors that impact eating behavior and weight. The study will describe the relationship between specific COVID-19 related stressors (e.g. fear of becoming sick) and self-rated me...

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
https://clinicaltrials.gov/ct2/show/NCT04901195

May 20th, 2022 - The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Assessing PA-824 for Tuberculosis (the APT Trial)
https://clinicaltrials.gov/ct2/show/NCT02256696

May 20th, 2022 - Phase IIB, 12-week, open-label, single-site, randomized clinical trial with three treatment groups. Patients with drug-sensitive TB will all receive once daily isoniazid and pyrazinamide for 8 weeks followed by 4 weeks of daily isoniazid. In addition, Arm 1 participants will receive PA-824 200 mg daily and rifampin 600 mg daily for 12 weeks. Arm 2 participants will receive PA-824 200 mg daily a...

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults
https://clinicaltrials.gov/ct2/show/NCT04896086

May 20th, 2022 - This is a Phase I, open-label, dose escalation study to evaluate the dose, safety, tolerability, and immunogenicity of the mosaic quadrivalent influenza vaccine VRC-FLUMOS0111-00-VP (FluMos-v1). The hypotheses are that the FluMos-v1 vaccine is safe and tolerable and will elicit an immune response. The primary objective is to evaluate the safety and tolerability of the investigational vaccine in...

Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection
https://clinicaltrials.gov/ct2/show/NCT00001645

May 20th, 2022 - This study is designed as a prospective study to evaluate and treat patients with parasitic infection. Patients with known or suspected parasitic infection will be enrolled and will be evaluated for the presence of a parasitic infection. Minimal studies scheduled for each visit will include a medical history, physical examination, routine laboratory tests and specialized diagnostic procedures f...

Studies of Blood and Reproductive Fluids in HIV-Infected and Non-HIV-Infected Persons
https://clinicaltrials.gov/ct2/show/NCT00001281

May 20th, 2022 - We are studying virologic and/or immunologic parameters of HIV infection and other infectious or non-infectious immune deficiency diseases in order to better understand the pathogenesis of HIV. Because of the lack of an adequate animal model it is generally necessary to utilize human peripheral blood cells for studying aspects of either in vivo or in vitro HIV infection. We wish to be able to c...

Host Response to Infection and Treatment in Filarial Diseases
https://clinicaltrials.gov/ct2/show/NCT00001230

May 20th, 2022 - Patients admitted on this protocol will have, or be suspected of having, one of the filarial infections affecting humans. After routine clinical evaluation they will be studied in depth immunologically, and their blood cells and/or serum will be collected to provide reagents (eg., specific antibodies, T-cell clones, etc.) that will be used in the laboratory to address the broader questions of d...

Natural History of Treated Neurocysticercosis and Long-Term Outcomes
https://clinicaltrials.gov/ct2/show/NCT00001205

May 20th, 2022 - The purpose of this protocol is to follow participants with cysticercosis during and after completion of treatment, to characterize the disease course during both short- and long-term follow-up, assess biomarkers associated with infection and response to treatment, improve diagnostic assays, and explore host-parasite interactions. Cysticercosis is defined as an infection with the larval form of...

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
https://clinicaltrials.gov/ct2/show/NCT00006150

May 20th, 2022 - The Hyper IgE Syndromes (HIES) are primary immunodeficiencies resulting in eczema and recurrent skin and lung infections. Autosomal dominant Hyper IgE syndrome (AD-HIES; Job's syndrome) is caused by STAT3 mutations, and is a multi-system disorder with skeletal, vascular, and connective tissue manifestations. Understanding how STAT3 mutations cause these diverse clinical manifestations is critic...

Progression of Spinal Fusion in Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT00085995

May 20th, 2022 - Spinal fusion is the clinical, radiological, and pathological hallmark of ankylosing spondylitis (AS). However, spinal fusion occurs slowly in AS. Serial radiographs rarely show changes over 2 years, and often 5 or more years are needed to demonstrate progression of spinal fusion. Methods that are more sensitive to changes in the extent of spinal fusion than plain radiographs are needed to test...

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
https://clinicaltrials.gov/ct2/show/NCT00004850

May 20th, 2022 - At initiation of this study in 1991, approximately 0.6% of U.S. blood donors were identified as having antibody to the hepatitis C virus (anti-HCV). This represented 72,000 of the estimated 12 million annual U.S. blood donations. By investigating a cohort of anti-HCV positive donors, this study aims to determine: 1) the primary routes of HCV transmission in an asymptomatic donor population; 2) ...

Molecular Basis of Erythrocyte Invasion by Plasmodium Vivax Into Duffy-Negative Erythrocytes in Mali
https://clinicaltrials.gov/ct2/show/NCT03304691

May 20th, 2022 - Plasmodium vivax was thought not to be a problem in Duffy blood group negative Africans. However, recent research has found that P. vivax infection occurs not only in areas where Duffy-positive and -negative people live side-by-side, but also in areas where populations are predominantly Duffy-negative, such as Bandiagara, Mali. In this region, our research group recently observed 25 P. vivax in...

Community Dynamics of Malaria Transmission and Mosquito Feeding in Bancoumana, Mali
https://clinicaltrials.gov/ct2/show/NCT03304704

May 20th, 2022 - A vaccine that interrupts malaria transmission is critical to eradicate the disease, but improved assays are needed to measure the efficacy of vaccines. Transmission-blocking vaccines (TBVs) work by inducing antibodies in vaccinees that inhibit parasite development in the mosquito interrupting transmission. Efficacy of vaccines may be estimated by in vitro membrane feeding assays using immune s...

Study of Mycobacterial Infections
https://clinicaltrials.gov/ct2/show/NCT00018044

May 20th, 2022 - The nontuberculous mycobacteria (NTM) are ubiquitous environmental organisms foundin soil and water that rarely cause disease in humans. Since exposure to these organisms is universal and disease is rare, it can be concluded that normal host defenses are almost always sufficient to prevent infection. It follows that otherwise healthy individuals who develop disease must have abnormal susceptibi...

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
https://clinicaltrials.gov/ct2/show/NCT03300830

May 20th, 2022 - Background: The availability of high quality, clinically annotated patient samples is crucial for the study of biologic factors that influence the natural history of viral related malignancies, malignancies occurring in the setting of HIV, and Castleman disease Comprehensive genomic sequence of viral-associated malignancies, malignancies occurring in the setting of HIV, tumors hypothesized to b...

Asymptomatic Congenital CMV Treatment
https://clinicaltrials.gov/ct2/show/NCT03301415

May 20th, 2022 - This is a phase II, open-label trial to evaluate valganciclovir as a treatment to prevent development of sensorineural hearing loss (SNHL) in infants with asymptomatic congenital cytomegalovirus (CMV) infection. The trial will be conducted in two phases - screening of newborns to identify eligible subjects, and treatment of those newborns who have confirmed CMV infection at birth but without ou...

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
https://clinicaltrials.gov/ct2/show/NCT00867269

May 20th, 2022 - Idiopathic CD4+ lymphocytopenia (ICL) is a disorder characterized by decreased numbers of circulating CD4+ T lymphocytes in the absence of known causes of CD4+ lymphocytopenia. ICL is defined as an absolute CD4+ T cell count of less than 300 cells/microL in a patient with no human immunodeficiency virus infection or known immunodeficiency syndrome. The causes and frequency of the disorder remai...